Pharmaceuticals | Healthcare | Exports | Corporate Development
Alembic Pharmaceuticals Receives USFDA Approval for Generic Prucalopride Tablets
Alembic Pharmaceuticals secures final USFDA approval for generic prucalopride tablets in 1 mg and 2 mg strengths, targeting a US$ 100 million reference market for the treatment of chronic idiopathic constipation in adults.
Published: 29 July 2026 Source: Alembic Pharmaceuticals Ltd. / US Food and Drug Administration (USFDA)
Approval Snapshot — Key Facts at a Glance
Final
USFDA Approval Status
Full ANDA final approval granted
1 mg & 2 mg
Approved Tablet Strengths
Generic Prucalopride Tablets
US$ 100M
US Reference Market Size
Equivalent to Rs. 940 crore
CIC Adults
Approved Indication
Chronic Idiopathic Constipation in adults
Overview
Alembic Pharmaceuticals Ltd. has secured a significant regulatory milestone in the United States pharmaceutical market with the receipt of final approval from the US Food and Drug Administration (USFDA) for its generic prucalopride tablets in 1 mg and 2 mg strengths. The approval pertains to the company’s Abbreviated New Drug Application (ANDA) filed for the treatment of chronic idiopathic constipation (CIC) in adults — a prevalent gastrointestinal condition affecting a significant segment of the US population.
The USFDA has confirmed the approved product as therapeutically equivalent to Takeda Pharmaceuticals USA Inc.’s branded product Motegrity, enabling Alembic Pharmaceuticals to enter the US market with a cost-effective, interchangeable generic alternative. The reference market for prucalopride tablets in the United States is estimated at approximately Rs. 940 crore (US$ 100 million), representing a meaningful commercial opportunity for the company.
This latest regulatory clearance further strengthens Alembic Pharmaceuticals’ USFDA-approved product portfolio and is consistent with the company’s long-term strategic objective of deepening its presence across regulated international pharmaceutical markets through a robust and diversified pipeline of generic medicines.
💊 Approval Details — Prucalopride Tablets
Applicant
Alembic Pharmaceuticals Ltd.
Regulatory Authority
US Food and Drug Administration (USFDA)
Product
Generic Prucalopride Tablets
Approved Strengths
1 mg and 2 mg
Therapeutic Indication
Chronic Idiopathic Constipation (CIC) in adults
Reference Listed Drug
Motegrity® — Takeda Pharmaceuticals USA Inc.
Application Type
Abbreviated New Drug Application (ANDA)
US Reference Market Size
Rs. 940 crore (US$ 100 million)
Business Significance
The USFDA approval for generic prucalopride tablets reinforces Alembic Pharmaceuticals’ broader strategy of building a competitive and diversified portfolio of generic medicines across high-value regulated markets. The United States, as the world’s single largest pharmaceutical market, remains a core focus for Indian pharmaceutical companies seeking to scale export revenues and establish long-term commercial footholds in premium regulatory jurisdictions.
Expanded US Generics Portfolio
The approval adds a commercially significant gastrointestinal generic product to Alembic’s growing suite of USFDA-cleared medicines, strengthening the depth and therapeutic breadth of its US portfolio.
Enhanced Export Revenue Potential
With a US reference market of approximately US$ 100 million, the approval opens a meaningful incremental revenue stream that supports Alembic’s broader objective of sustained export-led earnings growth from regulated markets.
Increased Regulated Market Penetration
Each new USFDA approval deepens Alembic’s market presence in the United States, one of the world’s most demanding yet most commercially rewarding pharmaceutical regulatory environments.
Validated R&D and Regulatory Capabilities
Receiving final USFDA approval signals successful navigation of the agency’s rigorous scientific, manufacturing and data review processes — validating the strength of Alembic’s internal research and compliance infrastructure.
India's Pharmaceutical Industry — Global Context
India has firmly established itself as one of the world’s foremost suppliers of high-quality, affordable generic medicines, accounting for a significant share of global generic pharmaceutical exports by both volume and value. The country’s pharmaceutical companies have built strong reputations across major regulated markets — including the United States, the European Union, the United Kingdom and Australia — through sustained investment in research and development, advanced manufacturing infrastructure and rigorous adherence to international quality standards.
Alembic Pharmaceuticals’ latest USFDA approval is emblematic of this broader trend, where Indian pharmaceutical manufacturers consistently demonstrate the technical capability and regulatory compliance required to introduce generic alternatives to complex branded medicines in highly regulated and commercially significant markets.
- Advanced research and development capabilities driving a robust ANDA pipeline
- World-class GMP-compliant manufacturing facilities audited by international regulatory bodies
- Stringent quality assurance and regulatory compliance standards meeting USFDA, EMA and other global requirements
- Competitive cost structures enabling affordable generic pricing without compromising product quality
- Expanding portfolio of complex generics targeting high-value therapeutic categories globally
Why This Development Matters
The United States pharmaceutical market is the world’s largest, accounting for roughly 40% of global pharmaceutical expenditure. For Indian generic manufacturers, securing USFDA approval is not merely a regulatory formality — it represents access to a commercially transformative market where generic medicines play an indispensable role in reducing healthcare costs and expanding patient access to essential treatments.
For Alembic Pharmaceuticals specifically, the prucalopride approval adds to a growing portfolio of USFDA-cleared products and demonstrates the company’s ability to compete in a market characterised by rigorous scientific standards, complex bioequivalence requirements and intense regulatory scrutiny. Each incremental USFDA approval also contributes to strengthening the company’s relationships with US pharmacy chains, wholesale distributors and group purchasing organisations.
From a broader national perspective, the development reinforces India’s stature as a trusted and indispensable supplier of affordable generic medicines to the global healthcare system — a position that carries both commercial and strategic value in an era of growing focus on pharmaceutical supply chain resilience.
Source: Alembic Pharmaceuticals Ltd. and the US Food and Drug Administration (USFDA). Approval pertains to the Abbreviated New Drug Application (ANDA) for generic Prucalopride Tablets, 1 mg and 2 mg, for the treatment of chronic idiopathic constipation (CIC) in adults. Motegrity® is a registered trademark of Takeda Pharmaceuticals USA Inc.
Disclaimer: This article is based on secondary research from official and publicly available sources. While FinIntelHub strives for accuracy, it does not guarantee the completeness or accuracy of the information.